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Newer antifungal therapy for emerging fungal pathogens 
William J. Steinbach(1,2) and John R. Perfect(2,3) 
As the number of immunocompromised patients increases, there is a concomitant increase in the number and 
diversity of fungal infections. Fungi that were once considered harmless or contaminants are now pathogenic in the 
immunocompromised host. Often these emerging pathogens are indistinguishable from the more familiar fungal 
infections; however, they are generally more recalcitrant to conventional antifungal therapies. With the antifungal 
armamentarium now expanding, the clinician now has many more options for these difficult-to-treat mycoses. We 
review many of the newer antifungal agents (second-generation triazoles, echinocandins, etc.) as therapeutic options 
for the recently emerging fungal pathogens. 
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As advances are made in the treatment of life-threaten- 
ing diseases with newer, aggressive chemotherapeutic 
regimens and the frequent use of bone marrow and 
organ transplantation, fungal pathogens are expanding 
in response to the increase in the number of immuno- 
compromised patients.l While Candida albicans, Asper- 
gillus fumigatus and Cryptococcus neoformans remain 
the most common invasive fungal pathogens in immuno- 
compromised hosts, changing environmental and host 
conditions, as well as selective antifungal pressure, have 
created newer patterns of emerging fungal diseases.2 
Clinicians must be aware of newer, infrequent pathogens 
that were once viewed as innocuous contaminants of 
cultures or ubiquitous harmless environmental inhabi- 
tants.3 It is clear that the number of fungal opportunistic 
pathogens is increasing,4 and the variety of species 
implicated has broadened, so that now the concept of a 
non-pathogenic fungus has to be justified in the setting 
of an immunocompromised host.5 These emerging fungal 
infections also often mimic the more common fungal 
infection presentations, and many can be lethal in im- 
munocompromised patients. In addition, these infect- 
ions can be resistant to conventional antifungal therapy, 
and, frequently, the numbers of infections treated 
successfully are so low that it is difficult to create a 
standard algorithm. 
The armamentarium of newer antifungals available 
has also recently increased, and may offer new ther- 
apeutic options for both the historically common patho- 
gens and the emerging diseases. There have been several 
excellent reviews on identifying the emerging fungal 
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pathogens,2T4Jj but there is no review focusing on the 
recent available data on the newer antifungals, such 
as amphotericin B lipid products, extended-spectrum 
triazoles, and echinocandins. Although analyzing all 
study results for every emerging fungal pathogen is 
beyond the scope of any single review, we will focus on 
a selection of these emerging pathogens and highlight 
the potential use of newer antifungal therapies. 
NON-ALBICANSCANDIDA SPECIES 
Background 
Candida albicans remains the most common Candida 
species. However, non-albicans Candida spp. have 
emerged as common nosocomial pathogens over the last 
decade.7 For instance, over a recent 2-year study period, 
a significant decrease was observed in the number of 
Candida albicans bloodstream isolates, with a con- 
comitant increase in the non-albicans Candida spp. iso- 
1ated.s Data from the National Cancer Institute revealed 
that the incidence of non-albicans Candida spp. in- 
fections increased from 22% in 1992 to 52% in 1997.” 
Furthermore, epidemiologic data from over 23 233 yeast 
isolates in 33 countries showed that Candida albicans 
was the most common isolate (67.3%), but was followed 
by substantial numbers of non-albicans Candida spp. 
such as Candida glabrata (9.5%), Candida tropicalis 
(5.3%), Candida parapsilosis (4.9%), Candida krusei 
(2.4%), Candida guilliermondii (0.9%), and Candida 
lusitaniae (O.5%).8 
These new Candida species can be more recalcitrant 
to standard antifungal therapy, either innately or due 
to selective antimicrobial pressure. Several important 
antifungal susceptibility patterns are emerging.‘” A 
susceptibility survey showed fluconazole resistance with 
Candida krusei and Candida glabrata, and less so with 
Candida parapsilosis and Candida guilliermondii.8 At 
present, Candida krusei is considered to be intrinsically 
resistant to fluconazole, while Candida glabrata is highly 
variable. Candida lusitaniae” and Candida guillier- 
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mondii develop resistance when treated with ampho- 
tericin B, and Candida parapsilosis may show tolerance 
to amphotericin B. The increase in the non-albicans 
Candida spp. that have been historically more difficult 
to treat, coupled with their own increased resistance to 
conventional antifungals, suggests the need for newer 
antifungals. 
The latest Candida species is Candida dubliniensis, 
first named in July 1995 by Sullivan et alI2 after they had 
isolated it from HIV patients with recurrent candidiasis 
at Dublin Dental Hospital. Candida dubliniensis isolates 
are phenotypically very similar to Candida albicans, 
producing germ tubes and chlamydospores, but other- 
wise yield unique assimilation profiles. Candida dublin- 
iensis is recovered from the oral cavities of approxi- 
mately 30% of HIV-infected patients with clinical oral 
candidiasis.i3 Its emergence is postulated to be due to 
the pressure of antifungal prophylaxis for Candida 
albicans in this patient population.6 One study reported 
that Candida dubliniensis also adheres to Vero cells 
significantly better in the presence of fluconazole,14 and 
a neutropenic murine model showed that Candida 
dubliniensis was more virulent than Candida albicans.15 
However, most studies of invasive candidiasis or 
candidemia have not identified Candida dubliniensis 
as a cause. Therefore, it remains unclear whether this 
species has any different response to antifungal therapy 
for invasive disease. 
In vitro analyses 
The majority of comparative studies with newer anti- 
fungals against Cundida spp. are in vitro susceptibility 
analyses. Although in vitro analyses may not predict in 
vivo outcome, and testing for some of the agents is not 
standardized, the results do give some general com- 
parative information. In vitro susceptibilities reported 
for newer antifungals against non-albicans Candida spp. 
are summarized in Table 1. The MICs were generally 
lower for the newer triazoles than for the echinocandins, 
but fungicidal activity was generally greater with the 
echinocandins.i6 
Animal or clinical experience 
There are few murine model studies with the less 
virulent non-albicans Candidu spp. that have tested 
newer antifungals; caspofungin has shown poor steriliza- 
Table 1. In vitro susceptibilities of non-albicans Candida species 
Species Ref. AMB FCZ ICZ vcz PCZ CAS MIC AND 
Candida tropicalis 
Candida parapsilosis 
Candida glabrata 
Candida krusei 
Candida lusitaniae 
Candida guilliermondii 
93 
75 
16 
86 
129 
130 
93 
75 
16 
86 
129 
130 
93 
75 
16 
86 
129 
130 
93 
75 
16 
86 
129 
130 
75 
16 
86 
129 
130 
93 
16 
86 
130 
0.125 8 0.5 0.0313 
0.5-l 4to >64 0.5 to z-8 0.0313-0.0625 
1.0 32 
2 
0.2 40 
0.5 1 
0.5-I 0.5-2 
1.0 2 . 
0.2a ;.32-0.64a 0.02a 
1 64 8 
0.25-0.5 2-8 0.25-I 
2 64 
8 
0.4 40 
1 64 
0.5-I >64 
1.0 16 
32 
0.8= 40a 
0.5 1 
2 2 
2 
0.1= 0.32-0.64 
0.25 4 
1.0= 2a 0.25" 0.06a 
0.4" s.o= 0.2a 
0.5 0.25 
0.8 
0.5 
0.13-0.5 
0.25 0.25 
2 0.5 
1.6 
1 
0.25-I 
1.0 0.5 
0.4a 
0.06-0.13 
0.25 0.06 
0.02a 
0.25 
0.5 
4 
1.0 
0.06 
0.299 
1.0 
0.5 
0.4 
2 
2 
0.2a 
1.0 
0.5 
0.4 
2 
1 
0.8a 
2 
2 
0.8a 
2" 
1.6= 
0.5 
2 
1 
0.25-2 
2 
>8.0 
0.0156 
<0.0078-0.0156 
0.25 
8 
0.125 
0.062Sto >4 
1.0 
0.0313-0.06256 
2 
>8.0 
2 
2* 
All values given as MICW (pg/mL) at 72 h of incubation, unless MIC range given, or specified as geometric mean MICa 
AMB, amphotericin B; FCZ, fluconazole; ICZ, itraconazole; VCZ, voriconazole; PCZ, posaconazole; CAS, caspofungin; MIC, micafungin; AND, anidulafungin. 
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tion of the kidney with Candida parapsilosis, but good 
activity against Candida tropicalis, Candida glabrata, 
Candida lusitaniae, and Candida krusei.17g18 Comparative 
clinical studies with amphotericin B and fluconazole 
for the treatment of candidemia have suggested that 
huconazole treatment outcome is similar to that with 
amphotericin B. 19,20 However, there have always been 
many fewer cases with non-albicans Candida spp. groups 
than with Candida albicans. Additionally, because of 
reduced in vitro susceptibility of non-albicans Candida 
spp., many clinicians will use amphotericin B as initial 
therapy for candidemia until the Candida species is 
identified. A recent large double-blind comparative 
study of amphotericin B versus caspofungin for treat- 
ment of candidemia and invasive candidiasis has been 
reported.21 In this study, caspofungin compared favor- 
ably with amphotericin B in the treatment of non- 
albicans Candida infections, in addition to causing 
substantially less drug toxicity. 
Candiduria with these yeasts remains common, and 
it is difficult to assess proper management. Candida 
tropicalis candiduria is difficult to eradicate with 
fluconazole,22 and the new triazoles and echinocandins 
do not have ideal pharmacokinetics for use in the 
treatment of urinary tract infections. Thus it is unlikely 
that new agents will help in the management of 
candiduria, and further prospective strategies for this 
condition will be necessary. 
Recommendations 
Fluconazole remains the treatment of choice for 
candidemia with susceptible isolates, since its activity 
appears to be equivalent to that of amphotericin B, 
with less toxicity. Several non-albicans Candida spp. are 
considered to be increasingly resistant to fluconazole 
(Candida krusei) or amphotericin B (Candida lusi- 
taniae), while others are relatively resistant.23 Guidelines 
now include treatment with fluconazole for Candida 
lusitaniae, due to increasing resistance to amphotericin 
B.24*25 The broad-spectrum anti-Candida activities, 
fungicidal properties, reduced drug interactions and 
safety may make caspofungin and other echinocandin- 
like drugs attractive therapeutic choices for these 
emerging yeast infections. The extended-spectrum 
triazoles such as voriconazole and posaconazole also 
have potent in vitro activity against many of the non- 
albicuns Candida spp., and initial open trials suggest that 
they possess therapeutic activity for invasive candidiasis, 
but comparative trials have yet to report the precise 
success of these agents. 
FUSARIUM SPECIES 
Background 
Fusarium spp. have been important soil-borne plant 
pathogens for years, 26 but are also becoming regular 
causes of keratitis and colonization of burn patient 
eschars. In immunocompromised patients they cause 
respiratory and disseminated infection and have become 
the second most common filamentous fungal pathogens 
after Aspergillus. The most common species of this 
ubiquitous mould include E solani (approximately 50% 
of Fusarium isolates), E moniliforme, E oxysporum, 
E dimerum, and E proliferatum.6 
Disseminated invasive fusariosis was first reported 
in 1973.27 It shares many pathogenic characteristics 
with invasive aspergillosis, including risk factors such 
as neutropenia and steroid use as well as a tropism 
for angio-invasion leading to hemorrhagic infarction.2 
Fusarium infections are acquired through respiratory 
inhalation and are seen in the lungs and sinuses, but are 
also increasingly being isolated from neutropenic 
patients with onychomycosis and concomitant toe or 
finger cellulitis as a source for disseminated disease.2,26,28 
Furthermore, one study recovered Fusarium spp. from 
57% of hospital water samples and used molecular 
methods to identify the hospital water system as a 
potential reservoir for exposure and disease.29 
In the largest published review, 91% (39/43) of 
patients presented with characteristic nodular cutaneous 
lesions,28 in which biopsy often showed extensive 
necrosis around hyaline branching septated hyphae.2 
Blood cultures were also positive in approximately 
one-half of cases. It is felt that the high rate of blood- 
stream recovery is due to the production of adventitious 
unicellular propagules, which, in conjunction with the 
vasotropism of Fusarium, might continuously release 
individual fungal cells into the bloodstream and seed 
the skin.30 Most Aspergillus species, except Aspergillus 
terreus, will not produce these propagules in tissue, 
and this represents an important difference in clinical 
presentation between aspergillosis and fusariosis. 
In vitro analyses 
The in vitro susceptibility data on newer antifungals for 
Fusarium infections are summarized in Table 2, and 
combination drug studies have also been reported. 
A checkerboard microdilution technique was used to 
investigate the activities of amphotericin B, ampho- 
tericin B +5fluorocytosine (5-FC) and amphotericin 
B +rifampin against R solani. One of five strains showed 
in vitro synergy with both amphotericin B+S-FC and 
amphotericin B+rifampin, with the remaining strains 
showing indifferent interactions. A checkerboard study 
with six Fusarium isolates and amphotericin B + 
caspofungin showed synergistic or additive interactions 
for most strains, with no antagonism.31 Finally, a com- 
bination study with 22 isolates of Fusarium spp. 
investigated the interaction between amphotericin B 
and the protein synthesis inhibitor and antibacterial 
azithromycin. The majority (85%) of isolates demon- 
strated amphotericin B resistance (MIC rl mg/mL), 
but when it was combined with azithromycin, MICs 
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Table 2. In vitro susceptibilities of Fusarium species 
Species Ref. AMB ICZ vcz PCZ RCZ CAS M/C AND TRB UR-9825 
Fusarium moniliforme 83 
75 
79 
131 
Fusarium oxysporum 83 
113 
16 
132 
87 
73 
75 
79 
51 
131 
133 
39 
Fusarium solani 83 
113 
16 
132 
87 
73 
75 
85 
79 
51 
131 
133 
93 
39 
4 >8 2 
l-2 2 to >8 
>16a 4a 2a 
I= 0.5-2 
1.0 >8 8 
1.0 >8 
2a >16a 8= 
0.25 to >64 0.5-2.0 
0.5-2 >8 
4to>16 8to>32 l-4 
I= 32a 4a 
0.5-2 0.25-2 
4a 22.6’ 2” 
5.65a 19.21” 
4 s8 >8 
4 >8 
I= >16a 8” 
>64 1.040 
2gm >8 
2 >I6 4 
1 to >I6 8 to >32 2-8 
Ia 32a 4a 
0.5-2 0.25-2 
4.39= >16a 4.16= 
0.25a >88 
17.52a 20a 
4.16a 
8” 
>16a 
>16a 
>I28 
>16a 
75.78a 
>I28 
>16= 
59.46= 
z-128 
>64a 
>16a 
8a 8a 
>16a 
4a 8a 
All values given as MI& (Fg/mL) at 72 h of incubation, unless MIC range given, or specified as geometric mean MICa 
AMB, amphotericin 8; ICZ, itraconazole; VCZ, voriconazole; PCZ, posaconazole; RCZ, ravuconazole; CAS, caspofungin; 
MIC, micafungin; AND, anidulafungin; TRB, terbinafine. 
were reduced by a mean of 3.2-fold. More importantly, 
the MICs were reduced from levels of resistance to 
levels achievable in serum.32 
Animal or clinical experience 
There are several studies evaluating drugs in controlled 
animal models of fusariosis. In a murine model, no 
differences were seen between controls, amphotericin B 
monotherapy, amphotericin B +5-FC, or amphotericin 
B+rifampin.33 This confirms a previous report of lack of 
amphotericin B activity in a murine mode1.34 In an 
immunocompetent murine model of fusariosis (E 
soluni), posaconazole showed a significant and dose- 
dependent effect on survival at 14 days, and therapy also 
resulted in complete clearance of the organism from the 
liver.35 A murine model showed that voriconazole was 
efficacious, being comparable to amphotericin B for 
fungal burden reduction in the kidney, and superior to 
amphotericin B for fungal burden reduction in the liver 
and brain.36 In another murine fusariosis model, high 
doses (20 mg/kg/day) of liposomal amphotericin B 
increased survival and reduced tissue burden compared 
with amphotericin B deoxycholate (1.5 mg/kg/day) and 
control groups.37 
Neutropenia is a prime risk factor for disseminated 
infection, and without recovery of neutrophils, Fusarium 
infection is fata1.28,38 The largest clinical review, 
including 43 cases of invasive fusariosis at one center 
and 54 cases from the literature, reported responses to 
therapy of 30% and 48%, respectively. Cure occurred 
uniformly only in those patients showing resolution of 
myelosuppression. 28 It is important to recognize this 
concept, and thus attention to immune reconstitution is 
necessary. In some cases, this may require granulocyte 
transfusions, but in most cases it will be necessary to 
attempt a rapid reversal of neutropenia with colony- 
stimulating growth factors. 
In the clinic, Fusarium infections can be relatively 
resistant to most standard antifungals3’ and a retro- 
spective survey of 31 human cases revealed nine 
different antifungal treatments used, with none being 
superior to the others. 4o Since invasive fusariosis often 
resembles aspergillosis, many patients have been treated 
with amphotericin B, which shows reduced in vitro 
activity against Fusarium spp.28,34 High doses of lipid 
formulations of amphotericin B can sometimes achieve 
stabilization of disease,4*,42 and one review showed 
improvement in 9 of 11 patients with 5 mg/kg per day of 
amphotericin B lipid complex.41 There have also been a 
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few clinical cases in which voriconazole has been used 
successfully for Fusarium spp. infections. For instance, a 
16-year-old girl with E solani keratitis after swimming in 
a lake showed no response with itraconazole therapy, 
and was changed to voriconazole at 4 mg/kg twice daily 
with clinical improvement, but relapsed after 10 days. 
The voriconazole dose was then increased to 6 mg/kg 
twice daily, the eye surgically debrided, and the anterior 
chamber irrigated with voriconazole, which finally led to 
clinical resolution.43 A patient with Fusarium peritonitis 
during continuous ambulatory peritoneal dialysis who 
failed catheter removal and amphotericin B treatment 
was cured with voriconazole treatment.44 In a multi- 
center study, voriconazole showed a positive response 
in approximately 50% of cases with fusariosis,45 and 
posaconazole showed a positive response in four of five 
patients with refractory fusariosis.46 
Recommendations 
In summary, invasive fusariosis can be extremely diffi- 
cult to diagnose and treat. In the immunocompromised 
patient, the clinical presentation often mimics invasive 
aspergillosis, but with some unique features. Standard 
doses of amphotericin B will have few consistent positive 
effects on infection. As with aspergillosis, attention to 
recovery of neutrophils is paramount, and control of the 
underlying disease is essential to a favorable outcome. 
Newer antifungal agents, such as high doses of lipid 
products of amphotericin B and the new extended- 
spectrum triazoles, may help control invasive infection 
in some patients until immune reconstitution has 
occurred, and they may represent a significant advance 
in the management of this difficult-to-manage mycosis. 
SCEDOSPORIUM SPECIES 
Background 
Scedosporium is a worldwide ubiquitous fungus 
recovered from soil, sewage, and animal manure. There 
are two medically important species: S. upiospermum is 
the asexual stage (anamorph) of Pseudallescheria 
boydii, and S. prolificans (formerly S. inflatum) is related 
to Pseudallescheria boydii.2 In normal hosts, these 
hyaline moulds produce localized disease after pene- 
trating trauma or aspiration of polluted water with 
development of pneumonia or meningitis. However, in 
immunocompromised patients, they can parallel the 
clinical manifestations of aspergillosis or fusariosis and 
lead to pulmonary or disseminated infection.47@ 
Previously, S. apiospermum was associated with ‘white- 
grain’ mycetoma, and S. pro1iJican.s with subcutaneous 
infections and a predilection for cartilage and joint 
areas, but in recent years they have been recognized 
as important pathogens in neutropenic patients.49 The 
spores infect an individual via inhalation, ulcerative 
lesions in the gastrointestinal tract, surgical wounds, or 
inoculation from trauma. Spores reach target organs and 
produce hyphae that eventually sporulate in tissue and 
disseminate through the bloodstream to other organs, 
particularly the kidneys, lungs, and brain.50 Many 
disseminated infections are fatal despite antifungal 
therapy, but recovery from neutropenia may lead to 
survival. 
In vitro analyses 
The in vitro susceptibilities of Scedosporium infections 
to newer antifungals are summarized in Tables 3 and 4. 
However, there are several studies worth highlighting in 
which a new triazole UR-9825 (Uriach Laboratories, 
Barcelona, Spain) showed the best activity against S. 
prolijicans,6~48~49~51 offering a potential agent for a species 
that is very resistant to antifungal agents. Some clinicians 
advocate combination therapy for this infection, and the 
combination of itraconazole and terbinafine has been 
examined.52 One study, using the checkerboard tech- 
nique, showed in vitro interactions between itraconazole 
and terbinafine when used against 20 clinical isolates 
of S. prolificarts. While each drug showed general in- 
activity, synergy was seen in 95% (19/20) of isolates after 
48 h, using drug levels attainable in blood.53 Another 
study showed synergistic in vitro interactions between 
voriconazole and terbinafine when used against S. 
prolificans.54 
An in vitro study examining checkerboard macro- 
dilution to characterize combinations of amphotericin B 
and various azoles when used against 22 isolates of 
Pseudallescheria boydii showed additive or synergistic 
interactions and no antagonism for 67% of isolates. 
Amphotericin B +fluconazole displayed the greatest 
synergy (mean fractional inhibitory concentration index 
(FICI), 0.61), followed by amphotericin B+miconazole, 
and amphotericin B +itraconazole.55 Another study 
reported poor in vitro activity with amphotericin B 
alone, but synergistic activity with amphotericin B and 
pentamidine when used against clinical isolates oi S. 
prolificarts. 56 However, overshadowing all the in vitro 
combination reports is a review of 16 patients with 
scedosporiosis treated with amphotericin B + 5-FC, 
fluconazole or itraconazole in which all patients who did 
not recover from neutropenia died.50 
Animal or clinical experience 
Few animal models have been studied for this infection, 
but one murine model of Pseudallescheria boydii infec- 
tion showed that itraconazole was ineffective, while 
posaconazole was slightly more effective than flucona- 
zole, in survival and fungal burden reduction.s7 Most 
early reported clinical cases of S. prolificarts infection 
represented colonization or contaminated wound 
infection, but the number of disseminated cases is 
increasing, and disseminated infection is usually fatal.58 
A prospective sputum fungal culture screening study of 
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Table 3. In vitro susceptibilities of Scedosporium species 
Species Ref. AMB ICZ vcz PCZ RCZ CA.5 M/C AND TRB UR-9825 
Scedosporium 
apiospermum 83 
113 
132 
48 
134 
87 
73 
49 
85 
51 
Scedosporium 
prolificans 83 
113 
16 
48 
132 
134 
87 
53 
73 
49 
75 
79 
51 
8 
8, 4 
4a 
16 
16 
2 
0.5, 1.0 
2a 
0.5 
4 
16 
0.5a 
0.5 
2 
>16 
8 
2a 
0.12 to >64 0.12-0.5 
>I6 0.25 
4 0.5 
32= 0.5= 
>8 >8 >8 
>8 >8 
>I6 >32 4 
>16* >16a >16= 
>16 >I6 16 
16 
8 
2a 
16a 
>32 
>64 
>16 
0.25 
I= 
232 
4.0 
4 
1= 
32a 
2 
0.25 0.125 
>I6 
>8 
>16a 
16 16 
2a 
>32 2 
0.38a 
1 
>32* 2* 
4-8 4 
32 4 
8.83a 
4 to >64 
2 
0.5 
>32 16a 
All values given as Ml& (Pg/mL) at 72 h of incubation, unless MIC range given, or specified as geometric mean MICa 
AMB, amphotericin B; ICZ, itraconazole; VCZ, voriconazole; PCZ, posaconazole; RCZ, ravuconazole; CAS, caspofungin; 
MIC, micafungin; AND, anidulafungin; TRB, terbinafine. 
Table 4. In vitro susceptibilities of Pseudallescheria boydii 
Ref. AMB ICZ vcz PCZ 
- 
CAS MIC AND 
55 1.1= 0.45a 
75 2 so.01 5-0.25 128 
16 2.6a 0.76a 0.33a 1 .o= 1.3= 
86. 2.6a 0.76a 0.333 
All values given as MICgO (FglmL) at 72 h of incubation, unless MIC range given, or specified as geometric mean MIC.a 
AMB, amphotericin B; ICZ, itraconazole; VCZ, voriconazole; PCZ, posaconazole; CAS, caspofungin; MIC, micafungin; 
AND; anibulafungin. 
2.5a 
128 children with cystic fibrosis showed S. apiospermum 
in 8.6% of cultures,59 a markedly higher level than the 
< 1% prevalence in the general population.60 Scedo- 
sporium spp. were usually recovered from the lungs of 
cystic fibrosis patients already colonized with Asper- 
gillus fumigatus, and in most cases colonization was not 
associated with disease, raising the issue of appropriate 
management. However, two patients presented with 
symptoms of allergic bronchopulmonary disease, which 
leads to comparisons with allergic aspergillosis in cystic 
fibrosis and the potential use of antifungals to reduce 
symptoms. 
Case reports of success with older antifungal agents 
against scedosporiosis are confounded by adjunctive 
surgical management and varying recovery of host 
defenses.48 An immunocompetent patient with S. 
apiospermkm pulmonary disease had an initial response 
with itraconazole and later showed relapse, but was 
cured after changing to terbinafine.61 A woman with 
asthma on chronic steroid therapy developed an S. 
apiospermum lung abscess, and new lesions developed 
while she was on itraconazole therapy. Treatment was 
changed to voriconazole, which cured the infection after 
63 days of therapy. 47 Another patient with relapsed 
acute myeloid leukemia developed disseminated disease 
with S. apiospermum despite empirical febrile neutro- 
penia treatment with amphotericin B lipid complex (3 
mg/kg/day). Therapy was switched to voriconazole after 
in vitro susceptibilities revealed activity, and despite 
persistent neutropenia, the patient’s skin lesion 
decreased in size and fever was eliminated; however, he 
later developed intestinal perforation and died.‘j2 
An B-year-old boy with chronic granulomatous 
disease (CGD) and an S. apiospermum pulmonary 
abscess was initially treated with miconazole, then oral 
capsular itraconazole (30 mg/kg/day), and finally oral 
voriconazole plus subcutaneous interferon-gamma 
(IFN-y). Computed tomography showed marked 
improvement only after treatment with voriconazole. 
The same report documented a 13-year-old boy with 
CGD and an S. apiospermum lung abscess who was 
treated with miconazole for 15 days with no improve- 
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ment; oral capsular itraconazole (20 mg/kg/day) and 
IFN-7 cured his pulmonary disease.63 Voriconazole has 
also been successfully used to treat a Pseudullescheria 
boydii central nervous system (CNS) infection after 
failure with amphotericin B lipid complex, miconazole, 
and itraconazole. 64 A relatively larg e series of scedo- 
sporiosis patients (36) treated with voriconazole has 
been reported. Over 60% of S. apiospermum infections 
had a positive clinical response, but fewer than 30% 
of S. prolificans infections had a positive clinical res- 
ponse.6s 
Recommendations 
There is no proven effective therapy for disseminated 
Scedosporium disease. The therapeutic approach to 
Scedosporium infections involves complete surgical 
resection, with the role of antifungals probably being 
important, including a notable lack of response to 
amphotericin B. M There is a clear trend for better results 
with S. apiospermum than with S. prolificans. S. 
prolificans is more resistant to treatment compared to S. 
apiospermum, both in vitro, in a murine mode1,‘j7 and in 
clinical experience. It appears that few antifungal agents 
have consistent activity against S. prolificarts, but the 
extended-spectrum triazoles such as voriconazole or 
posaconazole may become agents of choice for S. 
apiospermum infections. 
PENICILLIUM MARNEFFEI 
Background 
Penicillium marrteffei, the only dimorphic and human 
pathogenic Penicillium species, has emerged as the third 
most common AIDS-defining illness in parts of 
Southeast Asia.68 The incidence of this disease has 
increased markedly since the first reported natural 
infection in 1973.6y From approximately 30 cases in 
1973-90, the incidence of this infection rose to over 160 
reported cases by 1995. 7” In approximately 80% of 
cases4 disseminated disease can begin as numerous 
necrotic papulonodular lesions2 on the face, upper 
trunk, pinnae, and arms. 7o The disease can also present 
with non-productive cough, generalized lymphadeno- 
pathy, fever, anemia, and weight 10ss.~~,~i Approximately 
half of the cases involve fungemia.70 Penicillium 
marneffei can mimic and often be misdiagnosed as other 
infections, such as tuberculosis, Pneumocystis carinii 
pneumonia, cryptococcosis, and histoplasmosis. The 
conidia in the environment probably enter through the 
respiratory tract and convert to the yeast form, against 
which pulmonary alveolar macrophages appear to be 
the primary pulmonary host defense. 
In vitro analyses 
An in vitro study of 30 isolates revealed susceptibility to 
itraconazole and ketoconazole, and intermediate 
activity of amphotericin B and fluconazole.68 TWO 
comparative in vitro studies showed terbinafine and 
itraconazole to have similar activity,72 and itraconazole 
and voriconazole to have identical activity.73 In another 
study, posaconazole showed better in vitro activity than 
itraconazole and amphotericin B against four isolates.74 
Micafungin showed the best in vitro activity when 
compared to fluconazole, itraconazole, miconazole, and 
amphotericin B. 75 In one combination antifungal study, 
nikkomycin Z + itraconazole showed in vitro additivity 
against Penicillium spp.76 
Animal or clinical experience 
Amphotericin B has been used as successful initial 
management of disseminated penicilliosis in immuno- 
compromised patients, but requires prolonged intra- 
venous therapy, and relapse is common. Amphotericin B 
followed by itraconazole is also effective (97.3%)y1 but 
itraconazole takes an average of 57 days to clear 
fungemia.77 A review of 74 clinical isolates showed that 
itraconazole generally possessed better in vitro activity 
than amphotericin B, fluconazole, and ketoconazole, and 
it is generally recommended for treatment.68 However, 
voriconazole has been used to successfully treat 9 of 10 
cases of disseminated penicillinosis.45 
Recommendations 
The increasing incidence of Penicillium marneffei 
appears to be linked to the HIV pandemic. Unlike some 
other emerging fungal pathogens, this organism remains 
sensitive to many antifungals. For severe cases, initial 
induction treatment with amphotericin B may be neces- 
sary before switching to an oral azole, such as itra- 
conazole. Although itraconazole is presently the azole of 
choice, newer triazoles are attractive and also offer oral 
formulations for chronic suppressive therapy. 
ACREMONIUM SPECIES 
Background 
Acremonium species cause hyalohyphomycoses, which 
are mycoses caused by filamentous fungi which have 
colorless septate hyphae in tissue. They are common in 
soil, plant debris, and rotting mushrooms, and Acre- 
monium kiliense is the most important among the 10 
species reported as causing infections in vertebrates. The 
immunocompetent host can form a mycetoma or develop 
an ocular infection after sustaining a penetrating injury.78 
Acremonium spp. can lead to a wide range of infections, 
from keratitis to disseminated disease, with the lung and 
gastrointestinal tract as apparent portals of entry.2,4 
The first case of Acremonium spp. infection other 
than mycetoma or ocular infection was described in 1932, 
but most have arisen since 1985.78 The largest review of 36 
localized or disseminated cases showed that the majority 
of disseminated cases occurred in immunocompromised 
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patients, and only approximately half could be cured, with 
complete resolution of disease dependent on neutrophil 
recovery. 78 Recognition of disseminated Acremonium 
infection is difficult, because specific signs and symptoms 
do not exist.78 Patients may present with a cutaneous 
nodule, papular skin rash, or fungemia. 
In vitro analyses 
In one study, itraconazole had no activity and voricona- 
zole had a marginally effective MIC for Acremonium 
kiZiense.73 Another study showed that voriconazole had 
the best in vitro activity compared to amphotericin B, 
fluconazole and itraconazole against Acremonium 
alabamensis and Acremonium strictum.79 Anidulafungin 
has no activity against Acremonium spp., but posa- 
conazole and caspofungin both possess some fungistatic 
activity against Acremonium strictum.16 A recent study 
showed the activities of voriconazole and ravuconazole 
to be similar, and superior to that of posaconazole, while 
the strains tested were resistant to amphotericin B and 
itraconazole.80 
Animal or clinical experience 
The rarity of Acremonium infections makes it difficult to 
adequately assess the best treatment regimen. Ampho- 
tericin B was previously recommended as initial 
therapy,81 and despite the in vitro resistance to azole 
treatment, the combination of surgery and azoles has 
often been successful.78 Voriconazole appears to have 
the greatest in vitro activity against Acremonium, but 
clinical reports of its effectiveness are lacking. 
Recommendations 
As with other fungal pathogens, the status of the host 
defense system is crucial. Acremonium infections are 
still rare but deadly, and the limited amount of clinical 
experience makes firm recommendations difficult. The 
echinocandins appear to have limited activity, while 
the newer triazoles may constitute beneficial adjunctive 
therapy in concert with boosting the host immune 
response. 
PHAEOHYPHOMYCOSIS: 
CLADOPHIALOPHORA BANTIANA 
AND BIPOLARIS SPP. 
Bacl&ound 
Phaeohyphomycosis comprises a heterogeneous group 
of fungal diseases characterized by dematiaceous 
(darkly pigmented) hyphal forms in tissue involving the 
skin, subcutaneous and deep tissue, and CNS. Owing to 
space limitations, we will limit our discussion to several 
prominent species that represent this group. Clado- 
phialophora bantiana is the cause of the majority of 
CNS phaeohyphomycosis, including patients who may 
have no apparent immunosuppression.82 CNS disease 
commonly presents with a headache and a focal neuro- 
logic deficit, frequently a hemiparesis.82 Bipolaris spp. 
represent the most common cause of phaeomycotic 
sinusitis, but may also cause pneumonia, fungemia, and 
disseminated infections.2 
In vitro analyses 
In vitro studies with Cladophialophora bantiana show 
similar low MICs for voriconazole, itraconazole, 
amphotericin B,83 and terbinafine.84 One study showed 
the activity of posaconazole to be slightly worse than 
that of itraconazole, but much better than those of either 
anidulafungin or caspofungin.16 Another study showed 
itraconazole MICs to be better than those of vori- 
conazole against seven isolates,73 while in another set of 
experiments voriconazole had superior in vitro activity 
to itraconazole and amphotericin B.85 
The in vitro activity of drugs against Bipolaris 
species is variable. Amphotericin B possessed better 
activity than voriconazole and itraconazole against 
Bipolaris hawaiiensis and Bipolaris spicifera.83 However, 
in another study, voriconazole showed better in vitro 
activity than amphotericin B, fluconazole, and itra- 
conazole.79 Voriconazole was also generally better than 
itraconazole against Bipolaris australiensis.73 In contrast, 
a study with six Bipolaris spp. isolates showed 
itraconazole to have the best activity, followed closely 
by voriconazole and amphotericin B,*(j and another 
study with 43 isolates showed that itraconazole and 
terbinafine both had high in vitro activity.84 In the 
evaluation of the echinocandins, itraconazole showed 
the best activity, with both voriconazole and posaconazole 
displaying good activity, and all were far better than 
caspofungin or anidulafungin.16 Comparing all available 
triazoles, posaconazole had the most activity, followed 
by itraconazole, ravuconazole, and voriconazole.80 An 
in vitro combination study with a nikkomycin Z and 
fluconazole combination showed additive effects.76 
Animal or clinical experience 
Including only culture-positive cases of CNS phaeo- 
hyphomycosis, the survival rate for this infection is only 
35% .82 CNS lesions may be best managed surgically, and 
the largest series of 30 cases revealed that those patients 
with single, encapsulated lesions did much better 
than those with multifocal disease. However, no patient 
who did not undergo surgery survived.Whether patients 
underwent neurosurgery alone or with antifungal 
therapy, the most important factor for cure was 
resectability of the lesion; antifungal therapy itself was 
not associated with improved survival.s2 This has been 
our experience with six to eight cases. Recently, we 
treated one patient with multiple inoperable Clado- 
phialophora bantiana brain lesions and a severe 
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congenital immunodeficiency with voriconazole + WC, 
with some resolution of infection radiographically. HOW- 
ever, several months into treatment he did eventually 
succumb to his infection. 
Recommendations 
CNS phaeohyphomycosis continues to cause a high 
mortality without surgical resection, and this may be 
the case for ail localized phaeohyphomycoses. The new 
extended-spectrum triazoles, such as voriconazole and 
posaconazole, show good in vitro activity against 
Cladophialophora bantiana, Bipolaris spp., and several 
other dematiaceous fungi, with some positive correlat- 
ing clinical experience. 4s These agents may become 
attractive as adjunctive therapy for these phaeohypho- 
mycoses. Although the triazoles are probably more 
effective, the echinocandins do have some limited 
activity,87 and these agents will probably be tried in 
refractory cases as combination therapy. 
TRICHOSPORON SPECIES 
Background 
The incidence of fungemia caused by Trichosporon spp. 
is increasings8 in patients with hematologic malignancies 
and neutropenia, and this fungemia has been reported 
as the second most common yeast infection in cancer 
patients after Candida ~pp.~s One study showed that 
10% of all fungemias at one institution were caused by 
Trichosporon spp. 88 The taxonomy of Trichosporon has 
been revised several times recently. The most frequently 
reported species are Trichosporon asahii (formerly 
Trichosporon beigelii and Trichosporon cutaneum), 
Trichosporon pullulans, and Trichosporon capitatum 
(formerly Blastoschizomyces capitatus).88,89 Culture 
identification of Trichosporon spp. may be difficult, as it 
is often morphologically confused with Candida spp., 
which is worrisome, as Trichosporon has decreased 
susceptibility to amphotericin B, the drug often em- 
pirically used for suspected Candida infections. 
In vitro analyses, and animal and clinical experience 
There are limited in vitro studies and clinical reports 
for Trichosporon spp. One study of 39 Trichosporon 
clinical isolates showed high MICs for amphotericin 
B, with those of fluconazole and itraconazole being 
relatively lower. Ravuconazole, posaconazole and 
voriconazole appeared to be more active than ampho- 
tericin B or fluconazole, and similar to itraconazole, 
with voriconazole and posaconazole being slightly 
more active than ravuconazole. There were also 
potential fungicidal effects with the three newer 
triazoles.‘” In vitro studies with Trichosporon spp. 
showed that voriconazole was more active than 
itraconazole, amphotericin B, and fluconazole.79+86191 
Notably, Trichosporon pullulans has been found to be 
more resistant to antifungals, including total resistance 
to amphotericin B and fluconazole.” 
Further in vitro work showed posaconazole and 
amphotericin B to be similar, and superior to itra- 
conazole and fluconazole.74 Lipid formulations of 
amphotericin B had higher MICs against Trichosporon 
spp. than amphotericin B, liposomal nystatin, and 
itraconazole.92 Posaconazole showed good activity 
against Trichosporon beigelii, and the echinocandins 
caspofungin and anidulafungin showed no activity.i6 
This was echoed in further studies with micafungin75%93 
and anidulafungin. 94 There are some reports of clinical 
isolates that are resistant to both amphotericin B and 
azoles,95,96 leaving fewer antifungal class options. 
Clinically, the genus often causes catheter-related 
fungemia, but there are reports of endocarditis,97 peri- 
tonitis9s meningitis,99 and pneumonitis.loO Trichosporon 
spp. have limited susceptibility to amphotericin B,99 and 
earlier clinical studies and animal models showed that 
azoles were effective,‘Ol and azoles plus polyenes were 
potentially additive.‘(n In one study, 5 of 12 reported 
cases occurred while the patient was on itraconazole 
prophylaxis. Additionally, 11 of the 12 patients died 
despite amphotericin B therapy.88 The mortality of 
hematogenous trichosporonisis was higher than that of 
candidiasis in that study, confirmed by a review of the 
published literature of the last 20 years, showing a 
Trichosporon spp. mortality of 64-80%s8 and central 
venous catheters to be the most frequent risk factor 
for fungemia. Invasive Trichosporon beigelii infection 
has also developed in a bone marrow transplant patient 
who was receiving caspofungin prophylaxis against 
Aspergillus infection, lo3 highlighting the in vitro in- 
activity of this new class of antifungals against Tricho- 
sporon. 
Recommendations 
Trichosporon spp. cause very high mortality in immuno- 
compromised patients, and, as with most emerging 
fungi, resolution of immunosuppression is essential. 
Unfortunately, the genus is generally less susceptible to 
amphotericin B, the drug usually used in suspected yeast 
infections. This, coupled with the difficulty in dis- 
tinguishing the morphology of Candida and Tricho- 
sporon spp., may lead to delays in starting effective 
therapy. Azoles are generally more effective, and 
evidence exists to show that the newer triazoles might 
be the new treatment of choice. 
RHODOTORULA RUBRA 
Background 
Rhodotorula rubra is found naturally in soil, water, and 
plants, and is a constituent of the normal human 
respiratory, gastrointestinal and genitourinary flora.104 
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Previously, this organism was considered to be only 
a harmless colonizer when isolated from healthy 
individuals, but it is now being reported in immuno- 
compromised patients, causing fungemia, endocarditis, 
meningitis, and peritonitis.lo5 
In vitro analyses, and animal and clinical experience 
In vitro testing of 35 clinical samples of Rhodotor& spp. 
showed low MICs of amphotericin B, ketoconazole, 
flucytosine, and itraconazole. The azoles were generally 
less effective than amphotericin B, and fluconazole 
showed an MIC of >32 mg/mL against all isolates.86J06J07 
In a review of all 43 reported cases from 1960 to 2000, the 
most common risk for infection was central venous 
catheter insertion.104,108 It appears that the yeast is 
already an inhabitant of the skin and mucosa, and is 
introduced into the bloodstream following a disruption of 
normal anatomic barriers. In contrast to Trichosporon, 
mortality with Rhodotorula is uncommon, In a review, 10 
of 36 survivors of infection were not treated with 
antifungals, and appeared to respond to removal of the 
catheter. In a series of 23 cases of fungemia, the outcome 
was favorable with the use of various treatment strategies, 
including line removal alone, its removal with ampho- 
tericin B treatment, or antifungal therapy alone.ro5 Only 
two patients in this group of patients with Rhodotorula 
fungemia were neutropenic. 
Recommendations 
Although the need for antifungal therapy is not always 
clear for Rhodotorulu, if catheters are removed we 
would still be conservative and recommend antifungal 
therapy in the immunocompromised patient. However, 
it is clear that there is a predilection for catheter 
involvement and that fluconazole is probably not the 
optimal antifungal for use in this infection. 
TRICHODERMA LONGIBRACHIATUM 
Background 
Trichoderma spp. are ubiquitous in soil, with five species 
of the genus Trichoderma having been identified as 
etiologic agents of infection in immunocompromised 
hosts: Trichoderma Longibrachiatum, Trichoderma 
harzianum, Trichoderma koningii, Trichoderma 
pseudokoningii, and Trichoderma viride.5 Trichoderma 
longibrachiatum causes virtually all human infections, 
just as Penicillium marneffei is virtually the only 
pathogenic Penicillium species, and has been reported to 
cause pulmonary, cerebral, soft tissue, and disseminated 
disease in immunocompromised patients.2 It has been 
suggested that Trichoderma longibrachiatum can be 
acquired through the gastrointestinal tract, and pro- 
longed therapy with fluconazole and antibacterial agents 
may selectively favor this filamentous fungus.5 
In vitro analyses, and animal and clinical experience 
Itraconazole displays the best in vitro activity among the 
older antifungals in several studies.5J09-112 However, 
other studies showed that itraconazole had no activity, 
and amphotericin B had better activity than vori- 
conazo1e.83J13 The first case of Trichoderma infection in 
an immunocompromised patient was reported in 1976, 
and a recent review lists only 10 cases reported in 
immunocompromised hosts.5 Resistance to ampho- 
tericin B used for treatment of this infection has been 
common in these reported clinical cases. 
Recommendations 
The incidence of Trichoderma infections appears to be 
slowly increasing in immunocompromised patients. 
Extended-spectrum triazoles should be considered in 
preference to the polyenes for treatment, but recovery 
from immunosuppressive events appears to be crucial 
to success. Stool surveillance cultures for early identifi- 
cation of this fungus remain unproven for clinical 
management, but may play a role in future studies. 
PAECILOMYCES SPECIES 
Background 
Puecilomyces spp. are common soil saprophytes and 
occasional airborne laboratory contaminants. They are 
often confused with the Penicillium spp., and are 
clinically difficult to identify because their presentation 
can mimic that of better-known fungi such as 
dematiaceous fungi and certain hyalohyphomycoses.lr4 
They can cause keratitis, endophthalmitis and sub- 
cutaneous infections in the healthy host.4J14 In 
immunocompromised patients, they can manifest as 
cutaneous disease, catheter-related fungemia, sinusitis, 
and disseminated disease.2J14 Many immunocompro- 
mised patients become infected through integument 
breaks with intravascular catheters or chemotherapy.4 In 
fact, contaminated skin lotion has caused a nosocomial 
outbreak of infection in a bone marrow transplant 
unit.i15 
Fungemia can be seen, as with Fusarium spp. and 
Acremonium spp. When Fusarium spp., Paecilomyces 
spp. and Acremonium spp. invade tissue, they produce 
hyphae as well as adventitious structures similar to 
microconidia that hematogenously disseminate and are 
discovered on blood culture.l16 Aspergillus does not do 
this, except for Aspergillus terreus, which can elaborate 
lateral conidia in vitro and in vivo.2 
In vitro analyses 
Amphotericin B is very potent against Paecilomyces 
varioti, but has poor in vitro activity against the most 
common species, Paecilomyces lilacinus. Voriconazole 
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MICs are much lower than those of itraconazole for 
Paecilomyces lilacinus, including superior fungicidal 
activity,8” which was confirmed in another study, but 
the reverse was true for Paecilomyces varioti, with itra- 
conazole activity being better than that of voriconazole.” 
In a study with posaconazole, it was found to have similar 
activity to that of itraconazole and better activity than 
that of amphotericin B against Paecilomyces varioti. 
Posaconazole displayed significantly better activity 
against Paecilomyces lilucinus compared to itraconazole, 
while amphotericin B showed no activity against that 
species. 74 Comparing all triazoles, posaconazole had the 
most activity, followed by itraconazole, ravuconazole, and 
voriconazole.xO Caspofungin was inactive in vitro against 
Paecilomyces lilacinus, but showed excellent activity 
against Paecilomyces varioti.87 On the other hand, mica- 
fungin showed good in vitro activity against Paecilomyces 
lilacinus and Paecilomyces varioti, and better activity than 
fluconazole, itraconazole, miconazole, and amphotericin 
B.75 Nikkomycin Z + itraconazole combination therapy 
showed additivity in vitro against Paecilomyces sp~.‘~ 
Animal and clinical experience, and recommendations 
The cornerstone of therapy has been surgical resection 
and removal of any foreign objects.l14 In the clinic, host 
factors and surgery play an important role in the 
cure of this infection. Recent in vitro data suggest that 
the newer triazoles might be effective in treating 
Paecilomyces infections, but large data sets of clinical 
experience are lacking to support the recommendation, 
and it remains even less clear whether the echino- 
candins have any place in the management of these 
infections. 
ZYGOMYCETES 
Background 
Zygomycosis (formerly mucormycosis or phycomycosis) 
is a rare infection caused by fungi in the orders 
Mucorales (class Zygomycetes) and Entomophthorales, 
with the most common causative organisms being 
Mucor, Rhizopus, Absidia, and Rhizomucor.117~118 They 
are ubiquitous saprophytes found in the air, soil, and 
food. In a large review of 361 cases of human zygo- 
mycosis, the genus and species were reported in 156 
cases: 61% Rhizopus spp., 12% Mucor spp., and ~1% 
Rhizomucor spp. ’ I’) 
In vitro analyses 
In vitro studies examining the activities of various anti- 
fungals against clinical isolates of zygomycetes have 
shown that the most active drug is amphotericin B. With 
the exception of itraconazole inhibiting isolates from the 
genus Absidia, the early-generation azole compounds 
were generally inactive, and all isolates were resistant 
to flucytosine.‘20,121 One in vitro study with 37 clinical 
isolates of zygomycetes showed posaconazole to be the 
most active azole.‘22 
Animal and clinical experience 
Clinical manifestations of zygomycosis can be divided 
into the following categories: sinonasal, rhinocerebral, 
cerebral, pulmonary, cardiac, gastrointestinal, cutaneous, 
and disseminated.l*” Each category of disease requires a 
three-part management strategy: (1) early and aggressive 
surgical excision of the necrotic lesions; (2) restoration of 
immune function or control of underlying disease; and 
(3) intense antifungal therapy. Because tissue infarction 
is a prominent feature of infection with this angio- 
invasive fungus, removal of devitalized tissue is critical 
and can be curative for localized cutaneous zygomycoses 
associated with occlusive bandages, burns, or wounds, 
which rarely extend beyond local involvement.124 Surgical 
resection has been successful in cases of pulmonary 
disease.]*” Amphotericin B has been the mainstay of 
antifungal therapy to control residual infection after 
surgery for any early micrometastasis. Experience with 
lipid products of amphotericin B has been generally 
positive, with one study reporting successful outcome in 
71% of patients with zygomycosis treated with ampho- 
tericin B lipid complex. 126 The ability to give large doses 
of these formulations with reduced toxicity is attractive 
for treatment of these infections. 
The final management strategy is control of the 
underlying disease. In diabetic patients, this requires 
careful metabolic control during treatment, and cure is 
frequently obtainable. On the other hand, the mortality 
rate among patients with malignancy and zygomycosis 
continues to be very high, in contrast to the relatively 
good prognosis for patients with non-malignant under- 
lying diseases. 127 In these cancer patients, a favorable 
outcome correlates with non-pulmonary involvement, 
surgical debridement, and neutrophil recovery.l18 
Recommendations 
Surgical removal of affected tissue is a hallmark of 
therapy. Amphotericin B or its lipid formulations are 
used for invasive infection, and human studies will be 
necessary to determine whether posaconazole has any 
role in the management of zygomycosis. Control of the 
underlying disease or immunosuppression is essential 
for successful management of this infection. 
CONCLUSION 
The landscape of medical mycology is changing. 
Emerging pathogens that were once irritating con- 
taminants now lead to lethal disseminated disease in 
immunocompromised patients, and the once paltry list 
of antifungals available to combat this is increasing. 
However, coupled with the excitement of newer treat- 
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ment choices is the realization that nearly all of the 
evaluation of newer antifungals in these emerging 
pathogens comprises in vitro analyses, with limited 
animal and human experience. This is a crucial first step 
in establishing new treatments, but several caveats must 
be expressed. First, the science of in vitro antifungal 
susceptibility testing and clinical correlation is in its 
infancy, only recently establishing standards for yeasts 
and continuing studies into filamentous fungi.128 Addi- 
tionally, many in vitro studies test a limited number 
of isolates. Without further in vivo models or clinical 
reports, it is also difficult to ascertain the true pharmaco- 
kinetics, interactions and toxicities of these newer 
agents. Finally, the few anecdotal case reports published 
often include colony-stimulating factors or granulocyte 
transfusions as well as numerous other variables that 
could influence outcome, including improvement or 
deterioration in the underlying disease. 
We have attempted to compile available in vitro, in 
vivo and clinical data on the newer antifungal therapies 
available for some emerging fungal pathogens. Many 
of the fungal opportunists of today and tomorrow are 
innately or selectively resistant to conventional anti- 
fungals, so we desperately need to increase experience 
with these newer agents. As can be seen from this 
review, there are some baseline data for these emerging 
infections and newer drugs, but for the clinician it will 
take a creative individual approach to treat these 
infections. The issues will be to select a single antifungal 
agent or combination of antifungal agents, improve the 
patient’s immunity, and control the underlying disease. 
Success against these fungi will be determined by this 
three-pronged attack. 
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